- Home
- URGN vs CARS Comparison
URGN vs CARS Comparison
Compare URGN & CARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- CARS
- Stock Information
- Founded
- URGN 2004
- CARS 1998
- Country
- URGN United States
- CARS United States
- Employees
- URGN N/A
- CARS N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- CARS Motor Vehicles
- Sector
- URGN Health Care
- CARS Consumer Discretionary
- Exchange
- URGN Nasdaq
- CARS Nasdaq
- Market Cap
- URGN 904.0M
- CARS 815.4M
- IPO Year
- URGN 2017
- CARS 2017
- Fundamental
- Price
- URGN $18.94
- CARS $13.58
- Analyst Decision
- URGN Strong Buy
- CARS Strong Buy
- Analyst Count
- URGN 8
- CARS 5
- Target Price
- URGN $28.50
- CARS $17.30
- AVG Volume (30 Days)
- URGN 1.1M
- CARS 701.9K
- Earning Date
- URGN 11-05-2025
- CARS 11-06-2025
- Dividend Yield
- URGN N/A
- CARS N/A
- EPS Growth
- URGN N/A
- CARS 69.36
- EPS
- URGN N/A
- CARS 0.63
- Revenue
- URGN $94,238,000.00
- CARS $717,845,000.00
- Revenue This Year
- URGN $35.60
- CARS $2.52
- Revenue Next Year
- URGN $129.54
- CARS $2.93
- P/E Ratio
- URGN N/A
- CARS $21.87
- Revenue Growth
- URGN 10.85
- CARS 0.68
- 52 Week Low
- URGN $3.42
- CARS $9.56
- 52 Week High
- URGN $21.71
- CARS $20.47
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- CARS 57.42
- Support Level
- URGN $18.45
- CARS $13.15
- Resistance Level
- URGN $21.71
- CARS $13.84
- Average True Range (ATR)
- URGN 1.18
- CARS 0.40
- MACD
- URGN -0.17
- CARS 0.05
- Stochastic Oscillator
- URGN 20.90
- CARS 72.49
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CARS Cars.com Inc.
Cars.com Inc is an online destination for buying and selling new and used vehicles. It is an audience-driven technology company empowering the automotive industry. The company brands include Dealer Inspire, DealerRater, FUEL, Accu-Trade, PickupTrucks.com, CreditIQ, and NewCars.com., websites directed towards different consumer segments.